Developer docs
API playgroundTry for free, no card

Search company profiles

INEXION

Full company profile

uuid00r2cej

Namestring
INEXION
Legal namestring
INEXION Holdings, LLC
Websiteurl
inexion.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

INEXION operates a two-product platform built around a multi-source longitudinal health registry of de-identified longevity-medicine outcomes. The core registry combines three layers — an 8-dataset public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare; first three deployed in production, fourth arriving), de-identified contributions from cash-pay longevity clinics, telehealth platforms, and EHR partners under standard Data Use Agreements, and medical-society data flows via A4M and Longevity Docs — all unified under a single schema enforced at the integration layer. The schema-aligned architecture is the central technical decision: it lets INEXION add partners without acquisition CapEx, applies HIPAA Safe Harbor de-identification at source (18 specified identifiers), and makes data quality compound with each new contributor. The second product, INEXION Clocks, is practice-management software for longevity clinics that surfaces biological-age clock analytics, protocol-level outcome tracking, longitudinal patient timelines, and network benchmarking against the registry; demo complete with first deployments targeted for summer 2026.

The registry is the primary revenue engine. INEXION licenses data across four transaction-based streams: pharma HEOR studies ($150K-$400K each, 80%+ gross margin), sponsor-funded real-world evidence studies ($75K-$500K each, 75-85% margin), distributed trial-site identification and network access ($50K-$500K per engagement, 60-70% margin), and AI/ML training dataset subscriptions ($200K-$500K/year, 90%+ margin — highest-margin line). Customer segments are four named verticals: pharma HEOR and clinical operations at Lilly, Novo Nordisk, Pfizer, Amgen; longevity biotech R&D at Insilico, Life Biosciences, Rubedo (145+ active anti-aging trials worldwide); CROs and pharma sponsors for distributed trial-site networks; and AI/ML data science teams at Tempus, Saama, and similar firms. Go-to-market pairs an enterprise field-sales motion (direct outreach, discovery conversations under NDA, early-access partner program, joint study design) with a partner-led contributor enrollment model for clinics, telehealth platforms, EHR vendors, and medical societies. Ownership is founder-led, family-office-backed at seed (FO-led round targeting Q3 2026 close, extendable SAFE), with the company explicitly avoiding traditional VCs at seed to avoid exit pressure; Series A of $10-15M is structured FO-led with 1-2 strategic healthcare VCs co-investing, triggered on a Gate 2 composite of $500K ARR + 2+ active LOIs + 25K patient records + 3+ Type-1 partners by May 2027. Long-term pre-money targets are $40-53M at Series A, $150-180M+ at 2028 scale, and $500M-$1B at platform maturity, framed against comps Flatiron ($1.9B to Roche), Komodo ($3.3B), and IQVIA ($3.5B+ analytics revenue).

Short descriptiontext

INEXION operates a multi-source longitudinal registry of de-identified cash-pay longevity medicine outcomes, integrating a public-dataset spine with clinic, telehealth, EHR, and medical society data contributions for licensing to pharma HEOR, biotech R&D, CRO, and AI/ML buyers, alongside INEXION Clocks practice-management software for longevity clinics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
real-world evidence data, longevity medicine registry, de-identified health data, practice management software, HEOR data licensing
Industry3 codes
PRIMARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAHAI
Clinical & Claims Data Integration for Population Health (payer-provider data fusion)
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLAJANAM
Data Linkage, Registries & Longitudinal Cohort Surveillance
SIC code3 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Computer Programming Services7371
  • Services-Prepackaged Software7372
Product category
Real-World Evidence Data Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharma HEOR Data Licensing
TypeLicensing Royalties
Description

De-identified longitudinal registry licensed to pharma HEOR teams (Eli Lilly, Novo Nordisk, Pfizer, Amgen) running longevity-adjacent programs (GLP-1s, senolytics, NAD+ pathway modulators). $150K–$400K per study. Primary value-creation engine expected to re-rate business to platform multiples (15–20×+) at scale. 80%+ gross margin.

inexion.com
2Real World Evidence (RWE) Studies
TypeLicensing Royalties
Description

Sponsor-funded RWE through the partner network — registry data fees plus protocol-based study fees for comparator data, biomarker validation, and label expansion support. Buyers: Insilico Medicine, Life Biosciences, Rubedo Life Sciences. $75K–$500K per study. 75–85% gross margin. Network-effect compounding as partner base grows.

inexion.com
3Distributed Trial Site Network Identification
TypeLicensing Royalties
Description

Site identification, qualification, and contracting fees from sponsors and CROs (Parexel, Syneos, ICON) — without operating the sites. $50K–$250K per matched site, plus $100K–$500K trial-network access fees. Uncontested category; no legacy network operates in longevity. 60–70% gross margin.

inexion.com
4AI/ML Training Datasets
TypeLicensing Royalties
Description

Multimodal longitudinal longevity data (EHR, wearable, PRO, imaging, genomic) licensed as training corpus to AI/ML programs across pharma and biotech, plus data science teams at Tempus, Saama, and similar firms. $200K–$500K per year. 90%+ gross margin — highest-margin revenue line. Data currently unbuyable in any form.

inexion.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details4 tiers
1Pharma HEOR study licensing: $150K–$400K per study, 80%+ gross margin
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

De-identified longitudinal registry data licensed per study to pharma HEOR teams. Buyers: Eli Lilly, Novo Nordisk, Pfizer, Amgen with active longevity-adjacent programs.

inexion.com
2RWE sponsor studies: $75K–$500K per study, 75–85% gross margin
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Sponsor-funded RWE through the partner network — registry data fees plus protocol-based study fees. Network-effect compounding as partner base grows.

inexion.com
3Trial site identification: $50K–$250K per matched site + $100K–$500K trial-network access fees, 60–70% margin
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Site identification and qualification fees for pharma sponsors and CROs (Parexel, Syneos, ICON). No legacy network competes in longevity trial site identification.

inexion.com
4AI/ML training datasets: $200K–$500K per year, 90%+ gross margin
ModelSubscriptionBilling cadenceAnnual
Notes

Annual licensing of multimodal longitudinal longevity data to AI/ML programs. Highest-margin revenue line. Data currently unavailable from any source.

inexion.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

INEXION builds and licenses a multi-source longitudinal health registry of cash-pay longevity patients — the cohort invisible to every claims-based data platform — by integrating a public-data spine (NHANES, BRFSS, HRS, etc.) with de-identified contributions from partner clinics, telehealth platforms, EHRs, and medical societies under a unified schema enforced at the integration layer. INEXION also sells INEXION Clocks, practice management software for longevity clinics featuring biological-age analytics, protocol tracking, and network benchmarking powered by the registry.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • $2.7B reference market (RWD licensing) growing to $7.1B by 2033 with zero longevity coverage in incumbent platforms
+2 more records
Product overview1 text field

INEXION operates a two-product platform serving the longevity medicine market: (1) the INEXION Registry — a multi-source longitudinal health registry combining a public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare), private partner contributions from longevity clinics and telehealth platforms, and medical society partnerships (A4M, Longevity Docs), structured under a unified schema enforced at the integration layer; and (2) INEXION Clocks — practice software for longevity clinics providing biological-age analytics, protocol tracking, longitudinal patient timelines, and network benchmarking built in. The two products form a flywheel: INEXION Clocks generates the de-identified patient data that feeds the registry, while the registry provides the benchmarking intelligence surfaced within Clocks. The registry is the primary revenue engine, licensed to pharma HEOR teams, biotech R&D, trial site networks, and AI/ML teams across four buyer segments.

Product and service2 records
1INEXION Registry
CategoryReal-world evidence registry platform
Description

A multi-source longitudinal health registry aggregating de-identified longevity medicine outcomes across three data layers: a public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare), private partner contributions from longevity clinics and telehealth platforms, and medical society partnerships. Schema-enforced at the integration layer. Licensed to pharma HEOR teams, biotech R&D, clinical trial site networks, and AI/ML data science teams for HEOR studies, RWE, trial site identification, and AI/ML training datasets.

2INEXION Clocks
CategoryPractice management software for longevity clinics
Description

Practice management software built for longevity clinics, featuring biological-age analytics, protocol tracking, longitudinal patient timelines, and network benchmarking against de-identified peers powered by the INEXION registry. Operates as a thin overlay on existing systems without EHR migration, with HIPAA-grade privacy and standard Data Use Agreement onboarding. Early-access clinics receive founding pricing and direct line into product roadmap.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Los Angeles-based longevity clinic. Data exchange agreement structured for data contribution and licensing revenue share. Activates Q3 2026. One of the first anchor partners for the INEXION registry, establishing the partnership model for future clinic integrations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

In late-stage negotiation for data contribution to the INEXION registry. Partnership would add a high-volume telehealth platform to the partner network, expanding the cash-pay longevity cohort captured in the registry.

Strategic tierCoreTypeTechnology or Integration
Description

Named as Track 2 EHR partnership lead with term sheet target October 2026. Reya.ai would serve as an EHR integration partner enabling structured data flow from longevity practices into the INEXION registry schema.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

In active partnership discussions. Society partnership brings physician network breadth — practitioners contribute to the registry under a unified schema. A4M is the largest professional organization in anti-aging and longevity medicine.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

In active partnership discussions. Medical society partnership to drive physician network breadth and registry contributor recruitment. Jointly advances the longevity medicine evidence base.

6NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare (Public-Data Spine)
Strategic tierCoreTypeOthers
Description

Eight public datasets form the population baseline spine of the INEXION registry. NHANES, BRFSS, and HRS deployed today. MIDAS arriving within weeks. All of Us, UK Biobank, MIDUS, and CMS Medicare in pipeline. Provides population-level baseline for cohort comparisons against private partner cohorts.

inexion.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Truveta aggregates de-identified EHR data from a health-system consortium under a unified schema for life sciences licensing, structurally similar to INEXION's partnership-led schema-enforced registry model.

TypeEmerging player
Description

Panalgo provides real-world evidence analytics software that lets life sciences teams run analyses against large healthcare datasets, overlapping with INEXION's pharma RWE use cases.

TypeEmerging player
Description

Atropos Health delivers on-demand real-world evidence from de-identified clinical data to clinicians and life sciences teams, competing for the same pharma RWE and HEOR budget pools as INEXION.

TypeDirect peer
Description

ConcertAI builds oncology-focused real-world evidence and clinical research data products licensed to pharma, overlapping with INEXION's HEOR, RWE, and trial-site-identification revenue lines.

TypeBroad incumbent
Description

IQVIA is the dominant healthcare data and analytics incumbent ($3.5B+ analytics revenue) that INEXION positions against for pharma HEOR and RWE spend, while highlighting IQVIA's architectural blindness to cash-pay longevity cohorts.

TypeDirect peer
Description

Verana Health operates specialty real-world data registries (notably in ophthalmology and neurology) by partnering with medical societies to aggregate de-identified clinical data under a unified schema—the same partnership-led registry model INEXION is replicating for longevity medicine.

7Tempus
TypeBroad incumbent
Description

Tempus is a named AI/ML training data buyer candidate for INEXION and operates multimodal real-world clinical and molecular data at scale across oncology and beyond. Comparable as a buyer/peer in the AI/ML training corpus category.

TypeDirect peer
Description

Flatiron built an oncology-focused longitudinal EMR data registry licensed to pharma for HEOR and RWE, ultimately acquired by Roche for $1.9B. INEXION explicitly cites the Flatiron outcome as its engineering blueprint in longevity rather than oncology.

TypeDirect peer
Description

COTA curates oncology real-world evidence datasets and analytics for pharma and providers, closely paralleling INEXION's registry-licensing model in a different therapeutic vertical.

TypeBroad incumbent
Description

Komodo operates a claims-based healthcare data platform valued at $3.3B that INEXION identifies as architecturally blind to cash-pay longevity patients. It represents the incumbent RWD alternative for pharma HEOR and RWE spend.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INEXION

Real-World Evidence Data Platforminexion.com

INEXION operates a multi-source longitudinal registry of de-identified cash-pay longevity medicine outcomes, integrating a public-dataset spine with clinic, telehealth, EHR, and medical society data contributions for licensing to pharma HEOR, biotech R&D, CRO, and AI/ML buyers, alongside INEXION Clocks practice-management software for longevity clinics.

What INEXION does

INEXION operates a two-product platform built around a multi-source longitudinal health registry of de-identified longevity-medicine outcomes. The core registry combines three layers — an 8-dataset public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare; first three deployed in production, fourth arriving), de-identified contributions from cash-pay longevity clinics, telehealth platforms, and EHR partners under standard Data Use Agreements, and medical-society data flows via A4M and Longevity Docs — all unified under a single schema enforced at the integration layer. The schema-aligned architecture is the central technical decision: it lets INEXION add partners without acquisition CapEx, applies HIPAA Safe Harbor de-identification at source (18 specified identifiers), and makes data quality compound with each new contributor. The second product, INEXION Clocks, is practice-management software for longevity clinics that surfaces biological-age clock analytics, protocol-level outcome tracking, longitudinal patient timelines, and network benchmarking against the registry; demo complete with first deployments targeted for summer 2026.

The registry is the primary revenue engine. INEXION licenses data across four transaction-based streams: pharma HEOR studies ($150K-$400K each, 80%+ gross margin), sponsor-funded real-world evidence studies ($75K-$500K each, 75-85% margin), distributed trial-site identification and network access ($50K-$500K per engagement, 60-70% margin), and AI/ML training dataset subscriptions ($200K-$500K/year, 90%+ margin — highest-margin line). Customer segments are four named verticals: pharma HEOR and clinical operations at Lilly, Novo Nordisk, Pfizer, Amgen; longevity biotech R&D at Insilico, Life Biosciences, Rubedo (145+ active anti-aging trials worldwide); CROs and pharma sponsors for distributed trial-site networks; and AI/ML data science teams at Tempus, Saama, and similar firms. Go-to-market pairs an enterprise field-sales motion (direct outreach, discovery conversations under NDA, early-access partner program, joint study design) with a partner-led contributor enrollment model for clinics, telehealth platforms, EHR vendors, and medical societies. Ownership is founder-led, family-office-backed at seed (FO-led round targeting Q3 2026 close, extendable SAFE), with the company explicitly avoiding traditional VCs at seed to avoid exit pressure; Series A of $10-15M is structured FO-led with 1-2 strategic healthcare VCs co-investing, triggered on a Gate 2 composite of $500K ARR + 2+ active LOIs + 25K patient records + 3+ Type-1 partners by May 2027. Long-term pre-money targets are $40-53M at Series A, $150-180M+ at 2028 scale, and $500M-$1B at platform maturity, framed against comps Flatiron ($1.9B to Roche), Komodo ($3.3B), and IQVIA ($3.5B+ analytics revenue).

INEXION firmographics

Firmographics
Name
INEXION
Legal name
INEXION Holdings, LLC
Website
https://inexion.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
INEXION operates a multi-source longitudinal registry of de-identified cash-pay longevity medicine outcomes, integrating a public-dataset spine with clinic, telehealth, EHR, and medical society data contributions for licensing to pharma HEOR, biotech R&D, CRO, and AI/ML buyers, alongside INEXION Clocks practice-management software for longevity clinics.
Ownership category
akta.pro rank

INEXION industry classification

Industry
Product category
Real-World Evidence Data Platform
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Programming Services (7371), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAHAI
Clinical & Claims Data Integration for Population Health (payer-provider data fusion)
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLAJANAM
Data Linkage, Registries & Longitudinal Cohort Surveillance

Keywords

  • Real-world evidence data
  • Longevity medicine registry
  • De-identified health data
  • Practice management software
  • HEOR data licensing

Where INEXION is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

INEXION business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Pharma HEOR Data Licensing: De-identified longitudinal registry licensed to pharma HEOR teams (Eli Lilly, Novo Nordisk, Pfizer, Amgen) running longevity-adjacent programs (GLP-1s, senolytics, NAD+ pathway modulators). $150K–$400K per study. Primary value-creation engine expected to re-rate business to platform multiples (15–20×+) at scale. 80%+ gross margin.
  2. Real World Evidence (RWE) Studies: Sponsor-funded RWE through the partner network — registry data fees plus protocol-based study fees for comparator data, biomarker validation, and label expansion support. Buyers: Insilico Medicine, Life Biosciences, Rubedo Life Sciences. $75K–$500K per study. 75–85% gross margin. Network-effect compounding as partner base grows.
  3. Distributed Trial Site Network Identification: Site identification, qualification, and contracting fees from sponsors and CROs (Parexel, Syneos, ICON) — without operating the sites. $50K–$250K per matched site, plus $100K–$500K trial-network access fees. Uncontested category; no legacy network operates in longevity. 60–70% gross margin.
  4. AI/ML Training Datasets: Multimodal longitudinal longevity data (EHR, wearable, PRO, imaging, genomic) licensed as training corpus to AI/ML programs across pharma and biotech, plus data science teams at Tempus, Saama, and similar firms. $200K–$500K per year. 90%+ gross margin — highest-margin revenue line. Data currently unbuyable in any form.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goPharma HEOR study licensing: $150K–$400K per study, 80%+ gross margin
Transaction based/ take ratePay-as-you-goRWE sponsor studies: $75K–$500K per study, 75–85% gross margin
Transaction based/ take ratePay-as-you-goTrial site identification: $50K–$250K per matched site + $100K–$500K trial-network access fees, 60–70% margin
SubscriptionAnnualAI/ML training datasets: $200K–$500K per year, 90%+ gross margin

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

INEXION product offering

Product offering

Core offering

INEXION builds and licenses a multi-source longitudinal health registry of cash-pay longevity patients — the cohort invisible to every claims-based data platform — by integrating a public-data spine (NHANES, BRFSS, HRS, etc.) with de-identified contributions from partner clinics, telehealth platforms, EHRs, and medical societies under a unified schema enforced at the integration layer. INEXION also sells INEXION Clocks, practice management software for longevity clinics featuring biological-age analytics, protocol tracking, and network benchmarking powered by the registry.

Product overview

INEXION operates a two-product platform serving the longevity medicine market: (1) the INEXION Registry — a multi-source longitudinal health registry combining a public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare), private partner contributions from longevity clinics and telehealth platforms, and medical society partnerships (A4M, Longevity Docs), structured under a unified schema enforced at the integration layer; and (2) INEXION Clocks — practice software for longevity clinics providing biological-age analytics, protocol tracking, longitudinal patient timelines, and network benchmarking built in. The two products form a flywheel: INEXION Clocks generates the de-identified patient data that feeds the registry, while the registry provides the benchmarking intelligence surfaced within Clocks. The registry is the primary revenue engine, licensed to pharma HEOR teams, biotech R&D, trial site networks, and AI/ML teams across four buyer segments.

Differentiator

Problem solved

Functional benefit

Products and services

  • INEXION Registry A multi-source longitudinal health registry aggregating de-identified longevity medicine outcomes across three data layers: a public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare), private partner contributions from longevity clinics and telehealth platforms, and medical society partnerships. Schema-enforced at the integration layer. Licensed to pharma HEOR teams, biotech R&D, clinical trial site networks, and AI/ML data science teams for HEOR studies, RWE, trial site identification, and AI/ML training datasets.
  • INEXION Clocks Practice management software built for longevity clinics, featuring biological-age analytics, protocol tracking, longitudinal patient timelines, and network benchmarking against de-identified peers powered by the INEXION registry. Operates as a thin overlay on existing systems without EHR migration, with HIPAA-grade privacy and standard Data Use Agreement onboarding. Early-access clinics receive founding pricing and direct line into product roadmap.

Quantifiable outcome

  • $2.7B reference market (RWD licensing) growing to $7.1B by 2033 with zero longevity coverage in incumbent platforms
  • +2 more outcomes

Companies that use INEXION

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles5 records

INEXION technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

INEXION partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • HealthspancoreStrategic or Co-development Partner · 1 February 2026Los Angeles-based longevity clinic. Data exchange agreement structured for data contribution and licensing revenue share. Activates Q3 2026. One of the first anchor partners for the INEXION registry, establishing the partnership model for future clinic integrations.
  • AgelessRxcoreStrategic or Co-development PartnerIn late-stage negotiation for data contribution to the INEXION registry. Partnership would add a high-volume telehealth platform to the partner network, expanding the cash-pay longevity cohort captured in the registry.
  • Reya.aicoreTechnology or IntegrationNamed as Track 2 EHR partnership lead with term sheet target October 2026. Reya.ai would serve as an EHR integration partner enabling structured data flow from longevity practices into the INEXION registry schema.
  • A4M (American Academy of Anti-Aging Medicine)majorStrategic or Co-development PartnerIn active partnership discussions. Society partnership brings physician network breadth — practitioners contribute to the registry under a unified schema. A4M is the largest professional organization in anti-aging and longevity medicine.
  • Longevity DocsmajorStrategic or Co-development PartnerIn active partnership discussions. Medical society partnership to drive physician network breadth and registry contributor recruitment. Jointly advances the longevity medicine evidence base.
  • NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare (Public-Data Spine)coreOthersEight public datasets form the population baseline spine of the INEXION registry. NHANES, BRFSS, and HRS deployed today. MIDAS arriving within weeks. All of Us, UK Biobank, MIDUS, and CMS Medicare in pipeline. Provides population-level baseline for cohort comparisons against private partner cohorts.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

INEXION competitors and assessment

Company assessment

Emerging players

  • Truveta: Truveta aggregates de-identified EHR data from a health-system consortium under a unified schema for life sciences licensing, structurally similar to INEXION's partnership-led schema-enforced registry model.
  • Panalgo (Norstella): Panalgo provides real-world evidence analytics software that lets life sciences teams run analyses against large healthcare datasets, overlapping with INEXION's pharma RWE use cases.
  • Atropos Health: Atropos Health delivers on-demand real-world evidence from de-identified clinical data to clinicians and life sciences teams, competing for the same pharma RWE and HEOR budget pools as INEXION.

Direct peers

  • ConcertAI: ConcertAI builds oncology-focused real-world evidence and clinical research data products licensed to pharma, overlapping with INEXION's HEOR, RWE, and trial-site-identification revenue lines.
  • Verana Health: Verana Health operates specialty real-world data registries (notably in ophthalmology and neurology) by partnering with medical societies to aggregate de-identified clinical data under a unified schema—the same partnership-led registry model INEXION is replicating for longevity medicine.
  • Flatiron Health: Flatiron built an oncology-focused longitudinal EMR data registry licensed to pharma for HEOR and RWE, ultimately acquired by Roche for $1.9B. INEXION explicitly cites the Flatiron outcome as its engineering blueprint in longevity rather than oncology.
  • COTA Healthcare: COTA curates oncology real-world evidence datasets and analytics for pharma and providers, closely paralleling INEXION's registry-licensing model in a different therapeutic vertical.

Broad incumbents

  • IQVIA: IQVIA is the dominant healthcare data and analytics incumbent ($3.5B+ analytics revenue) that INEXION positions against for pharma HEOR and RWE spend, while highlighting IQVIA's architectural blindness to cash-pay longevity cohorts.
  • Tempus: Tempus is a named AI/ML training data buyer candidate for INEXION and operates multimodal real-world clinical and molecular data at scale across oncology and beyond. Comparable as a buyer/peer in the AI/ML training corpus category.
  • Komodo Health: Komodo operates a claims-based healthcare data platform valued at $3.3B that INEXION identifies as architecturally blind to cash-pay longevity patients. It represents the incumbent RWD alternative for pharma HEOR and RWE spend.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

INEXION social profiles

Digital presence

INEXION financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INEXION leadership team

Management profile

Number of profiles

Profiles6 records

INEXION funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INEXION M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INEXION

What does INEXION do?

INEXION builds and licenses a multi-source longitudinal health registry of cash-pay longevity patients — the cohort invisible to every claims-based data platform — by integrating a public-data spine (NHANES, BRFSS, HRS, etc.) with de-identified contributions from partner clinics, telehealth platforms, EHRs, and medical societies under a unified schema enforced at the integration layer. INEXION also sells INEXION Clocks, practice management software for longevity clinics featuring biological-age analytics, protocol tracking, and network benchmarking powered by the registry.

Is INEXION a public or private company?

INEXION is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was INEXION founded?

INEXION was founded in 2025. It employs 1 to 10 people.

Where is INEXION based?

INEXION is headquartered in Austin, United States, in the North America region.

How does INEXION make money?

Four revenue lines are on record. Pharma HEOR Data Licensing is the primary driver. The others are real World Evidence (RWE) Studies, distributed Trial Site Network Identification and AI/ML Training Datasets.

Who are INEXION's main competitors?

Emerging players on record are Truveta, Panalgo (Norstella) and Atropos Health. Direct peers are ConcertAI, Verana Health, Flatiron Health and COTA Healthcare. Broad incumbents are IQVIA, Tempus and Komodo Health.

Does INEXION have an API?

No public API is recorded for INEXION.

What industry is INEXION in?

INEXION's product category is Real-World Evidence Data Platform. Its primary akta.pro industry code is HLACAHAH, Patient Registries & Chronic Disease Registry Analytics, with a secondary code of HLACAHAI, Clinical & Claims Data Integration for Population Health (payer-provider data fusion). Its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales